Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Authors :: Massimo Offidani
Michele Cavo
Daniele Derudas
Francesco Di Raimondo
Antonio Cuneo
Luca Baldini
Roberta Della Pepa
Maurizio Musso
Mario Boccadoro
Pellegrino Musto
Maria Teresa Petrucci
Angelo Belotti
Source :: Blood. 140:7222-7223
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools